Cadila Healthcare

Cadila Pharma launches quadrivalent influenza vaccine 'Cadiflu Tetra'

Cadiflu Tetra is developed employing Nano-sized particles, the Vaccine mimics the external structure of the virus without containing intact genetic material

Zydus Lifesciences' Rs 750 cr-share buyback open between June 23-July 6

The drug firm, earlier known as Cadila Healthcare, has fixed July 15, 2022 as the last date for the settlement of bids on stock exchanges which may even happen early, as per a regulatory filing.

Covid-19: Zydus gets SEC approval for two-dose regimen of ZyCov-D

Zydus to conduct mixing trials to test vax efficacy after two shots of Covishield/Covaxin

Stocks to Watch: TCS, Veranda, Voda Idea, Exim Bank, Cadila, Banks, IT

TCS is likely to announce results after market hours on Monday. The IT stocks will be in focus with Infosys too to announce earnings later this week.

Cadila Pharma launches world's first novel 3-dose vaccine against rabies

The three-dose vaccine, named as 'ThRabis', is a recombinant nano-particle based G protein vaccine which is prepared using Virus-like Particle technology

Six Indian drug firms that are doing serious business in coronavirus times

The world's race for a coronavirus drug hinges on Indian companies working with their global peers. Business Standard tracks six companies to feel the pulse of Indian pharma

Stocks to Watch: Gail, Apollo Hospitals, Cadila, IOC, UPL, Saregama, KSB

Apollo Hospitals is likely to be in limelight as the stock enters Nifty 50. It will be replacing IOC with effect from March 31.

Cadila Healthcare changes name to Zydus Lifesciences Limited

Unveils 'innovation and care' centric corporate brand identity

Zydus Pharma gets final USFDA approval to market Roflumilast tablets

Zydus, being one of the first applicants for Roflumilast Tablets, 500 mcg, is eligible for 180 days of shared generic drug exclusivity

Stocks to Watch: RIL, ITC, TCS, Titan, Cadila, Emami, Lupin, EIH, Tyre

BoI, Devyani Intl, Eveready, FSL, Mahindra Life, Paytm, REC, Siemens, Sintex, SPARC, Tata Steel, Thermax and Vijaya Diagnostics are some of the prominent companies to announce results today.

Zydus Q3 net down 5% to Rs 500 cr as sales dip in US and domestic markets

Revenue from operations nearly flat at Rs 3,655 crore in reporting quarter

Stocks to Watch: Tech Mahindra, Adani Ports, Hero Moto, Voda Idea, TTML

Adani Green, Apollo Tyres, Adani Total Gas, Balrampur Chini, Dabur, eClerx, HDFC, IOB, Jubilant Foodworks, M&M Financial, Tata Consumer and Zee to announce results today.

Cadila Healthcare's US arm receives FDA nod to market Pimavanserin capsule

Cadila Healthcare on Friday said its US arm Zydus Pharmaceuticals (USA) Inc has received tentative approval from the US health regulator to market generic Pimavanserin capsules, indicated for treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The approval by the US Food & Drug Administration for the generic Pimavanserin capsules is for the strength of 34 mg, Cadila Healthcare said in a regulatory filing. "The drug will be manufactured at the group's formulation manufacturing facility at SEZ Ahmedabad," it said. The group now has 325 approvals and has so far filed over 400 abbreviated new drug applications (ANDAs) since the commencement of the filing process in FY 2003-04, it added.

Cadila Healthcare inks ZyCoV-D commercialisation agreement with Korean firm

Cadila will provide manufacturing license and transfer the Plasmid DNA vaccine technology to Enzychem Lifesciences

Stocks to Watch: DLF, Airtel, Vedanta, Cadila, Escorts, Voda Idea, Zen Tech

The SGX Nifty indicates a quiet start for our markets this morning

Sensex, Nifty end with marginal losses; M&M rallies 5% post Q2 results

Among sectors, the BSE Auto index jumped 1.3 per cent. The Capital Goods, Energy and Oil & Gas indices were also up around a per cent each. The Metal index, however, was down 0.8 per cent

Cadila Healthcare gets Central govt order to supply 10 mn doses of ZyCoV-D

ZyCoV-D is the first DNA plasmid vaccine in the world for human use, developed indigenously by the company against the Covid-19 virus

Cadila Healthcare Q2 PAT up by 6% YoY to Rs 597 cr, revenue up 3%

The company's EBIDTA margin for the quarter was 22.7 per cent, up by 50 basis points

Q2 preview: Non-Covid revenues to hint at normalisation for healthcare cos

Companies may, however, report sequential drop in numbers as Q1FY22 coincided with outbreak of second Covid wave, say brokerages

Cadila gets DCGI nod to conduct phase III trials for two-dose Covid vaccine

Shares of Cadila Healthcare Ltd were trading at Rs 563.95 per scrip on BSE, up 0.29 percent from their previous close.